Lisata Therapeutics, Inc.

NasdaqCM:LSTA Stock Report

Market Cap: US$24.2m

Lisata Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Lisata Therapeutics has a total shareholder equity of $33.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $38.2M and $4.8M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$35.86m
EquityUS$33.44m
Total liabilitiesUS$4.76m
Total assetsUS$38.20m

Recent financial health updates

Recent updates

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Jul 15
Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?

Mar 22
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Sep 15
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Caladrius rallies on approval of merger, name change to Lisata Therapeutics

Sep 14

Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01

Aug 04

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

May 02
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate

Jan 05
We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate

Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth

May 09
Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth

Caladrius suspends CLBS119 COVID-19 study

Dec 14

Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation

Nov 30
Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation

Financial Position Analysis

Short Term Liabilities: LSTA's short term assets ($37.7M) exceed its short term liabilities ($4.7M).

Long Term Liabilities: LSTA's short term assets ($37.7M) exceed its long term liabilities ($72.0K).


Debt to Equity History and Analysis

Debt Level: LSTA is debt free.

Reducing Debt: LSTA had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LSTA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LSTA has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 4.2% each year.


Discover healthy companies